Holen Sie sich die Stockscreener-App
7.75
2.65%
0.20
Handel nachbörslich:
7.92
0.17
+2.19%
Schlusskurs vom Vortag:
$7.55
Offen:
$7.62
24-Stunden-Volumen:
709.79K
Relative Volume:
0.77
Marktkapitalisierung:
$243.00M
Einnahmen:
$19.09M
Nettoeinkommen (Verlust:
$-82.13M
KGV:
-2.7653
EPS:
-2.8026
Netto-Cashflow:
$-70.00M
1W Leistung:
+16.54%
1M Leistung:
-17.38%
6M Leistung:
-74.77%
1J Leistung:
-72.49%
1-Tages-Spanne:
$7.56
$7.91
1-Wochen-Bereich:
$6.66
$7.91
52-Wochen-Spanne:
$6.61
$50.40
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Firmenname
Lenz Therapeutics Inc
Sektor
Branche
Telefon
858-925-7000
Adresse
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Compare LENZ vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
7.75 | 236.73M | 19.09M | -82.13M | -70.00M | -2.8026 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-14 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-03-18 | Eingeleitet | TD Cowen | Buy |
| 2024-09-27 | Eingeleitet | Raymond James | Outperform |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-15 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-15 | Eingeleitet | William Blair | Outperform |
| 2024-04-10 | Eingeleitet | Citigroup | Buy |
| 2024-03-27 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-02-23 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-02-23 | Herabstufung | Cowen | Outperform → Market Perform |
| 2023-01-25 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-01-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-01-06 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-04-14 | Eingeleitet | BTIG Research | Buy |
| 2022-03-22 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-02-18 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-07-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-07-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Lenz Therapeutics Inc Aktie (LENZ) Neueste Nachrichten
Eye drop company LENZ heads to three investor conferences in June - Stock Titan
LENZ Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance
Earnings call transcript: LENZ Therapeutics sees growth in Q1 2026 By Investing.com - Investing.com Nigeria
LENZ Therapeutics (LENZ) price target decreased by 20.47% to 39.10 - MSN
LENZ Therapeutics, Inc. (LENZ) reports Q4 loss, misses revenue estimates - MSN
Users - FinancialContent
Industry Analysts Just Made A Stunning Upgrade To Their Maze Therapeutics, Inc. (NASDAQ:MAZE) Revenue Forecasts - Yahoo Finance
LENZ Therapeutics Q1 2026 earnings preview - MSN
Some LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Just Made A Major Cut To Next Year's Estimates - simplywall.st
Things Look Grim For LENZ Therapeutics, Inc. (NASDAQ:LENZ) After Today's Downgrade - Yahoo Finance
Earnings Update: LENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Reported And Analysts Are Trimming Their Forecasts - Sahm
LENZ Stock Price, Quote & Chart | LENZ THERAPEUTICS INC (NASDAQ:LENZ) - ChartMill
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - Moomoo
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Reported And Analysts Have Been Cutting Their Estimates - Yahoo Finance
LENZ Therapeutics, Inc. (LENZ) reports Q1 loss, beats revenue estimates - MSN
Citi Maintains LENZ Therapeutics(LENZ.US) With Buy Rating, Cuts Target Price to $20 - Moomoo
LENZ Therapeutics Company Profile & Introduction - Moomoo
MSN Money - MSN
A Quick Look at Today's Ratings for LENZ Therapeutics(LENZ.US), With a Forecast Between $12 to $60 - Moomoo
Lenz Therapeutics price target raised to $31 from $29 at BofA - TipRanks
LENZ Therapeutics stock price target lowered to $38 by H.C. Wainwright - Investing.com Nigeria
Lenz Therapeutics price target lowered to $38 from $48 at H.C. Wainwright - TipRanks
LENZ Therapeutics Q1 earnings call highlights - MSN
Lenz outlines sales force reaching 15,000 eye care professionals by quarter end as VIZZ adoption actions roll out - MSN
Lenz Therapeutics downgraded to Neutral from Overweight at Piper Sandler - TipRanks
Piper Sandler cuts Lenz Therapeutics stock rating on slow sales - Investing.com
Piper Sandler cuts Lenz Therapeutics stock rating on slow sales By Investing.com - Investing.com Australia
LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - The Manila Times
LENZ Therapeutics Q1 Earnings Call Highlights - inkl
Lenz Therapeutics Releases 2026 First Quarter Results - VisionMonday.com
Lenz Therapeutics reports Q1 EPS ($1.32), consensus ($1.07) - TipRanks
Lenz Therapeutics Earnings Call Balances Promise and Risk - TipRanks
LENZ: Q1 delivered 25,000 prescriptions, $1.9M revenue, and strong early adoption momentum - TradingView
TradingKey - TradingKey
Earnings call transcript: LENZ Therapeutics sees growth in Q1 2026 - Investing.com UK
LENZ: Q1 2026 delivered strong prescription growth and revenue, with robust cash and expanding adoption - TradingView
LENZ Therapeutics, Inc. (LENZ) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
LENZ Therapeutics (NASDAQ:LENZ) Q1 Report Shows Revenue Beat But Deepening Losses Sink Stock - ChartMill
LENZ THERAPEUTICS ($LENZ) Releases Q1 2026 Earnings - Quiver Quantitative
Finanzdaten der Lenz Therapeutics Inc-Aktie (LENZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lenz Therapeutics Inc-Aktie (LENZ) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Schimmelpennink Evert B. | President, CEO and Secretary |
Mar 27 '26 |
Buy |
8.95 |
28,089 |
251,411 |
77,289 |
| Chevallard Daniel R. | Chief Financial Officer |
Mar 27 '26 |
Buy |
8.57 |
7,500 |
64,275 |
12,886 |
| Olsson Shawn | Chief Commercial Officer |
Nov 17 '25 |
Option Exercise |
2.08 |
10,000 |
20,800 |
14,733 |
| Olsson Shawn | Chief Commercial Officer |
Nov 17 '25 |
Sale |
26.10 |
10,000 |
261,022 |
4,733 |
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):